Decoy Therapeutics, Inc. (Nasdaq: DCOY) announced on April 2, 2026, that it has regained compliance with the Nasdaq Listing Rule 5550(a)(2), which pertains to the Minimum Bid Price Requirement. This compliance was confirmed following a reverse stock split that took effect on March 6, 2026. The company had previously received notice from Nasdaq on December 31, 2025, indicating that its common stock had been trading below the required minimum bid price of $1.00 for 30 consecutive business days. In response, Decoy Therapeutics requested a hearing with the Nasdaq Hearings Panel, which allowed the company to stay any potential suspension or delisting actions while it worked to regain compliance.

During a hearing on February 6, 2026, Decoy presented its plans to meet the Minimum Bid Price Requirement, which included the implementation of a reverse stock split. Following the split, the company began trading on a split-adjusted basis on March 9, 2026. By March 20, 2026, Decoy's common stock closed at $7.47 per share, successfully demonstrating compliance with the Minimum Bid Price Requirement by trading above $1.00 for ten consecutive business days.

On March 31, 2026, the Hearings Panel confirmed that Decoy Therapeutics had regained compliance with all applicable continued listing requirements on The Nasdaq Capital Market. However, the company will remain under a Mandatory Panel Monitor until March 31, 2027, as per Nasdaq Listing Rule 5550(a)(2). This monitoring period will ensure that Decoy maintains compliance with the listing standards moving forward. The company’s leadership expressed optimism about the future and its ability to execute its strategic plans without the burden of delisting risks.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.